SCHEMBL10068040

SCHEMBL10068040

CCN[C@H]1CC[C@@H](C(=O)O)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
PLG P00747 1/20 0.43
PLAT P00750 1/20 0.43
ALDH1A1 P00352 3/20 0.40
SELL P14151 2/20 0.40
SELP P16109 2/20 0.40
SELE P16581 2/20 0.40
GAA P10253 1/20 0.39
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
TSHR P16473 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
GABRA4 P48169 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23525279 1.00 LMNA (0.43) LMNAPLGPLATALDH1A1SELL
SCHEMBL12056723 1.00 LMNA (0.43) LMNAPLGPLATALDH1A1SELL
SCHEMBL12997498 0.89 PLG (0.38) LMNAPLGPLATALDH1A1SELL
SCHEMBL13804200 0.89 PLG (0.38) LMNAPLGPLATALDH1A1SELL
SCHEMBL13804198 0.89 PLG (0.38) LMNAPLGPLATALDH1A1SELL
SCHEMBL13804255 0.89 PLG (0.38) LMNAPLGPLATALDH1A1SELL
SCHEMBL13804203 0.89 PLG (0.38) LMNAPLGPLATALDH1A1SELL
SCHEMBL23557994 0.83 PLG (0.41) LMNAPLGPLATALDH1A1SELL
SCHEMBL15160474 0.83 KCNH2 (0.38) ALDH1A1KCNH2METAP1EPHX1
SCHEMBL13024559 0.83 KCNH2 (0.38) KCNH2METAP1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021121282-A1 PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS WITH IMMUNOMODULATORY FUNCTION 上海轶诺药业有限公司 2021-06-24 WO disclosed
WO-2014028600-A2 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2014-02-20 WO disclosed
US-20120077711-A1 Novel Ligands and Libraries of Ligands SUNESIS PHARMACEUTICALS, INC. (US) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077711-A1 Novel Ligands and Libraries of Ligands LSS, ABCG2, SELL LMNA 317/4885PLG 2534/4885PLAT 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.